| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8623794 | Seminars in Arthritis and Rheumatism | 2018 | 28 Pages |
Abstract
Our strategy of upfront combination immunosuppressant therapy stabilised disease activity in 92.8% of patients, while 7.2% had true refractory disease. Relapse free survival was 66% at 5 years and 52% at 10 years. Damage progression was arrested in 68% and only 2 fatalities were observed. Initial steroid dose of 0.5Â mg/kg/day had similar efficacy as 1Â mg/kg/day dose.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Ruchika MD, DM, Debashish MD, DM, FRCP, George MD, DM, Raheesh MD, PDF, Sathish MD, DCH, Visali PhD, Lakshmanan PhD, Paul FRCP,